Wang Y, Wang Y, Li M
Centre of Infectious Desease, Southwest Hospital, Third Military Medical College, Chongqing.
Zhonghua Nei Ke Za Zhi. 1997 Oct;36(10):665-8.
This experiment was carried out to establish an optimal extracorporeal bioartificial liver support system (EBLSS) and furnish a new therapy for hepatic failure. For this purpose, human hepatocytes were isolated by two-stage perfusion method and cultured by spheroidal aggregates method. Besides, hollow fiber tube was used as bioreactor and the hemodialysis instrument was refited to serve as supplementary circulation unit, which was composed of EBLSS and was tried in normal dogs. A total of 2 x 10(10) human hepatocytes with a viability of 94% was obtained. These hepatocytes became multicellular spheroidal aggregates under non-adherent conditions. After 5 hours circulating on EBLSS, the hepatocytes remained active. At the same time, the monitoring system revealed a normal vital sign in dogs and the laboratory tests found their serum total protein and albumin were increased. These results show that the key technology of bioartificial liver has been dereloped basically and this EBLSS is effective and safe, providing a foundation for the support and treatment of hepatic failure with bioartificial liver.
本实验旨在建立一种优化的体外生物人工肝支持系统（EBLSS），并为肝衰竭提供一种新的治疗方法。为此，采用两步灌注法分离人肝细胞，并采用球状体聚集法进行培养。此外，使用中空纤维管作为生物反应器，并对血液透析仪进行改装以用作辅助循环单元，该单元由EBLSS组成，并在正常犬身上进行了试验。共获得了2×10¹⁰个活力为94%的人肝细胞。这些肝细胞在非贴壁条件下形成多细胞球状体聚集物。在EBLSS上循环5小时后，肝细胞仍保持活性。同时，监测系统显示犬的生命体征正常，实验室检查发现其血清总蛋白和白蛋白增加。这些结果表明，生物人工肝的关键技术已基本得到发展，且该EBLSS有效且安全，为生物人工肝支持和治疗肝衰竭奠定了基础。
